Abstract:Anti-cancer response of cell lines to drugs is in urgent need for individualized precision medical decision-making in the era of precision medicine. Measurements with wet-experiments is time-consuming and expensive and it is almost impossible for wide ranges of application. The design of computational models that can precisely predict the responses between drugs and cell lines could provide a credible reference for further research. Existing methods of response prediction based on matrix factorization or neural networks have revealed that both linear or nonlinear latent characteristics are applicable and effective for the precise prediction of drug responses. However, the majority of them consider only linear or nonlinear relationships for drug response prediction. Herein, we propose a Dual Branch Deep Neural Matrix Factorization (DBDNMF) method to address the above-mentioned issues. DBDNMF learns the latent representation of drugs and cell lines through flexible inputs and reconstructs the partially observed matrix through a series of hidden neural network layers. Experimental results on the datasets of Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) show that the accuracy of drug prediction exceeds state-of-the-art drug response prediction algorithms, demonstrating its reliability and stability. The hierarchical clustering results show that drugs with similar response levels tend to target similar signaling pathway, and cell lines coming from the same tissue subtype tend to share the same pattern of response, which are consistent with previously published studies. As is known, the phenotype of cancer is closely related to gene expression in the human body. In the era of precision medicine, an increasing amount of anti-cancer drug response data is urgently needed for individualized therapy. Measurements with wet-experiments are time-consuming and costly, and computational methods are necessary. Existing methods mainly focused predominantly on linear or nonlinear relationships between cells and drugs for prediction. However, it has been shown that both linear and nonlinear relationships could contribute to more precise response prediction. Here, we propose a Dual Branch Deep Neural Matrix Factorization (DBDNMF) method to better use both linear and nonlinear relationships and the experimental results show that it outperforms state-of-the-art algorithms. Our results suggest that drugs showing similar response levels tend to target similar signaling pathways while cell lines sharing similar response patterns tend to come from the same tissue subtype. The analysis of experimental results may benefit medical decision-making.

Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction

Identifying “Many-to-many” Relationships Between Gene-Expression Data and Drug-Response Data Via Sparse Binary Matching

A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer

Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity

Identifying Cancer Biomarkers by Network-Constrained Support Vector Machines.

Prediction of drug sensitivity based on multi-omics data using deep learning and similarity network fusion approaches

Drug Screening and Biomarker Gene Investigation in Cancer Therapy Through the Human Transcriptional Regulatory Network

Predicting drug synergy using a network propagation inspired machine learning framework

Discovering Explainable Biomarkers for Breast Cancer Anti-PD1 Response via Network Shapley Value Analysis

A Novel Approach For Drug Response Prediction In Cancer Cell Lines Via Network Representation Learning

Predicting Anticancer Drug Responses Using A Dual-Layer Integrated Cell Line-Drug Network Model

Network-based Identification of Micrornas As Potential Pharmacogenomic Biomarkers for Anticancer Drugs

Application of network link prediction in drug discovery

Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations

Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells

Predicting drug activity against cancer through genomic profiles and SMILES

Network-based machine learning approach to predict immunotherapy response in cancer patients

DBDNMF: A Dual Branch Deep Neural Matrix Factorization method for drug response prediction

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

Machine learning prediction of oncology drug targets based on protein and network properties

Network-based Multi-Task Learning Models for Biomarker Selection and Cancer Outcome Prediction.